

Sent: 19 January 2011 08:12

Subject: Final ACD and Evaluation Report and information on economic model for

the appraisal of Lapatinib and trastuzumab - first line (with an aromatase inhibitor)

Dear [REDACTED]

Thank you for the opportunity to comment on the appraisal consultation document and

evaluation report for the above health technology appraisal.

I wish to confirm that the Department of Health has no substantive comments to make

regarding this consultation.

Many thanks and best wishes

NICE Sponsor Team

Department of Health